Cardiac Troponin SMAs

About Bioventix

Bioventix is a specialist biotechnology company focused on the development and supply of high-affinity sheep monoclonal antibodies for the global in-vitro diagnostics (IVD) industry. Founded in 2004 and listed on the London AIM market, its core strategy is to identify diagnostic assays with unmet needs for better antibodies, develop superior SMAs, and license them to major diagnostic partners, generating stable, high-margin royalty revenue. The company has achieved consistent profitability and growth by leveraging its unique technological niche to become a critical, behind-the-scenes supplier to nearly all major global immunodiagnostics companies.

Therapeutic Areas

Other Acute Coronary Syndrome Drugs